← Leaderboards
Ashraf S. Ibrahim
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center
$17,102,127
Attributed
$20,072,177
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,277,390 · 18
By mechanism
R01$13,011,909 · 2
R44$2,987,094 · 1
P01$2,745,156 · 3
R33$1,369,478 · 1
R21$1,114,382 · 3
R43$599,778 · 1
Top collaborators
- Gary Lazar5 shared
- Tim Cooke1 shared
- John E. Edwards1 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPreventLifeFungusPathogenesisCellsMouse ModelVirulenceMucormycosisEndothelial CellsSerumNeutropeniaIronOperative Surgical ProceduresIncidenceIn VitroIn VivoInvadedImmunocompromised HostDiabetic KetoacidosisBlood VesselsGenesProteinsRhizopus
Grant awards (51)
Deciphering Immunopathogenesis of MUCORmycosis to ADVANCE Risk stratification, Diagnosis and Management of the Disease$2,205,213
P01 · FY2025 · AI · contact PI
Humanized monoclonal antibodies to treat mucormycosis$999,218
R44 · FY2025 · AI
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment$554,760
R01 · FY2025 · AI · contact PI
Project 1$408,054
P01 · FY2025 · AI · contact PI
Administrative Core$131,889
P01 · FY2025 · AI · contact PI
Humanized monoclonal antibodies to treat mucormycosis$999,975
R44 · FY2024 · AI
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment$554,760
R01 · FY2024 · AI · contact PI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens$1,151,780
R01 · FY2023 · AI · contact PI
Humanized monoclonal antibodies to treat mucormycosis$987,901
R44 · FY2023 · AI
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment$554,760
R01 · FY2023 · AI · contact PI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens$83,143
R01 · FY2023 · AI · contact PI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens$1,047,323
R01 · FY2022 · AI · contact PI
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment$554,760
R01 · FY2022 · AI · contact PI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens Supplement$38,411
R01 · FY2022 · AI · contact PI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens$1,022,514
R01 · FY2021 · AI · contact PI
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment$554,760
R01 · FY2021 · AI · contact PI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens$1,171,930
R01 · FY2020 · AI · contact PI
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens$1,181,298
R01 · FY2019 · AI · contact PI
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections$481,547
R33 · FY2019 · AI · contact PI
Novel Toxins and Receptors in Mucormycosis Pathogenesis$394,200
R01 · FY2019 · AI · contact PI
Humanized monoclonal antibodies to treat mucormycosis$299,778
R43 · FY2019 · AI
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections$430,815
R33 · FY2018 · AI · contact PI
Novel Toxins and Receptors in Mucormycosis Pathogenesis$394,200
R01 · FY2018 · AI · contact PI
Humanized monoclonal antibodies to treat mucormycosis$300,000
R43 · FY2018 · AI
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections$457,116
R33 · FY2017 · AI · contact PI
Novel Toxins and Receptors in Mucormycosis Pathogenesis$394,200
R01 · FY2017 · AI · contact PI
Novel Toxins and Receptors in Mucormycosis Pathogenesis$389,490
R01 · FY2016 · AI · contact PI
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections$197,100
R21 · FY2016 · AI · contact PI
Iron Uptake and Mucormycosis Pathogenesis$354,925
R01 · FY2015 · AI · contact PI
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections$164,250
R21 · FY2015 · AI · contact PI
Iron Uptake and Mucormycosis Pathogenesis$352,868
R01 · FY2014 · AI · contact PI
Iron Uptake and Mucormycosis Pathogenesis$329,800
R01 · FY2013 · AI · contact PI
Iron Uptake and Mucormycosis Pathogenesis$348,873
R01 · FY2012 · AI · contact PI
Iron Uptake and Mucormycosis Pathogenesis$346,935
R01 · FY2011 · AI · contact PI
An Ftr1 vaccine to abrogate mucormycosis$205,201
R21 · FY2011 · AI · contact PI
Iron Uptake and Mucormycosis Pathogenesis$269,001
R01 · FY2010 · AI · contact PI
An Ftr1 vaccine to abrogate mucormycosis$181,150
R21 · FY2010 · AI · contact PI
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS$4,147
M01 · FY2010 · RR · contact PI
Iron Uptake and Mucormycosis Pathogenesis$269,353
R01 · FY2009 · AI · contact PI
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS$6,283
M01 · FY2009 · RR · contact PI
Iron Uptake and Mucormycosis Pathogenesis$267,056
R01 · FY2008 · AI · contact PI
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS$7,894
M01 · FY2008 · RR · contact PI
Iron Uptake and Mucormycosis Pathogenesis$269,956
R01 · FY2007 · AI · contact PI
Novel Antifungal Strategies for Lethal Mucormycosis$193,669
R21 · FY2007 · AI · contact PI
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS$5,509
M01 · FY2007 · RR · contact PI
Novel Antifungal Strategies for Lethal Mucormycosis$173,012
R21 · FY2006 · AI · contact PI
Iron Uptake and Mucormycosis Pathogenesis$160,853
R01 · FY2006 · AI · contact PI
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS$748
M01 · FY2006 · RR · contact PI
Iron Uptake and Mucormycosis Pathogenesis$280,728
R56 · FY2005 · AI
Treatment of Fungal Infections with ATAK Cells$72,576
R03 · FY2004 · AI
Treatment of Fungal Infections with ATAK Cells$71,708
R03 · FY2003 · AI